转录组学市场－全球产业规模、份额、趋势、机会和预测，按组件、技术、应用、最终用户、地区和竞争细分，2020 年至 2030 年

2024年，全球转录组学市场规模达75.3亿美元，预计2030年将达102.8亿美元，预测期内复合年增长率为5.33%。全球转录组学市场正经历显着成长，这得益于发展中国家RNA定序和NGS在遗传疾病诊断中的应用日益广泛。此外，随着新型微阵列技术的引入，政府机构对新技术开发的积极性和投资不断增加，并显着增加了全球各地对转录组学的需求。此外，新技术的普及和个人化医疗治疗需求的不断增长，预计将进一步增加对转录组学的需求，从而推动市场成长。

此外，生物製药公司数量的不断增长以及研发支出的不断增加，预计将进一步增加对转录组学的需求，从而支持市场成长。在美国，每年每4.5分钟就有一名婴儿出生时患有先天缺陷，每33名美国新生儿中就有1名患有先天缺陷，这意味着大约有12万名婴儿受到影响。转录组学是研究转录组的学科，而转录组则是由基因组产生的一整套RNA转录物。

关键市场驱动因素

高通量定序技术的进展

主要市场挑战

复杂的数据解释和生物资讯瓶颈

主要市场趋势

多组学方法在疾病研究中的整合

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：临床试验分析

第六章：全球转录组学市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按组件（仪器、耗材、软体和服务）
  • 依技术（次世代定序、聚合酶炼式反应、微阵列、原位杂交、其他）
  • 按应用（药物发现与开发、细胞生物学、单细胞分析、基因表现、其他）
  • 按最终用户（生物技术与製药公司、学术与研究机构、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按组件
  • 依技术
  • 按应用
  • 按最终用户
  • 按地区

第七章：北美转录组学市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲转录组学市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太转录组学市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第十章：南美洲转录组学市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲转录组学市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 最新动态
• 併购
• 产品发布

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品/服务的威胁

第 15 章：SWOT 分析：全球转录组学市场

第 16 章：竞争格局

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Transcriptomics Market was valued at USD 7.53 billion in 2024 and is expected to reach USD 10.28 billion by 2030 with a CAGR of 5.33% during the forecast period. The global market for Transcriptomics is experiencing significant growth, driven by the growing application of RNA sequencing and NGS for the diagnosis of genetic illness in the developing countries. Additionally, growing initiative and investments by government organizations for developing new technology, with the introduction of new microarray technology have significantly increased the demand for transcriptomics across different parts of the globe. Additionally, the rising adoption of new technology and growing demand for personalized medicine for treatments are further expected to increase the demand for transcriptomics, thereby fuelling the market growth.

Furthermore, increasing number of biopharmaceutical companies and growing expenditure on research and development are further expected to increase the demand for transcriptomics, thereby supporting the market growth. Every 4 1/2 minutes, a baby is born with a birth defect in United States every year and affects 1 in every 33 babies born in the United States each year. That translates into about 120,000 babies. Transcriptomics is the study of the transcriptome, which is the complete set of RNA transcripts that are produced by the genome.

Key Market Drivers

Advancements in High-Throughput Sequencing Technologies

The rapid evolution and increased affordability of high-throughput sequencing technologies-particularly RNA sequencing (RNA-seq)-have significantly propelled the growth of the global transcriptomics market. RNA-seq enables the precise quantification of transcripts and discovery of novel RNA species across various sample types, thereby facilitating large-scale gene expression profiling in both basic research and clinical applications. Governments across the globe are investing heavily in next-generation sequencing (NGS) infrastructure. For instance, the U.S. National Institutes of Health (NIH) allocated over $1.5 billion in 2023 for initiatives linked to genomic medicine, including transcriptomics. NIH's All of Us Research Program has specifically emphasized the inclusion of RNA expression data to understand disease biology across diverse populations.

In addition, transcriptomics technologies are increasingly integrated into disease biomarker discovery, drug development pipelines, and personalized medicine. Projects such as the Genotype-Tissue Expression (GTEx) Project by the NIH have generated comprehensive gene expression datasets, enabling researchers to map tissue-specific gene expressions and variation across populations. The plummeting costs of RNA-seq-from over $1,000 per sample a decade ago to less than $100 today-have democratized access to these technologies. This price drop is particularly impactful for academic institutions and biotech companies in developing nations, driving adoption at a global scale. Moreover, automation in sample preparation, data analysis, and bioinformatics pipelines further accelerates throughput and reduces labor costs, enhancing scalability.

Key Market Challenges

Complex Data Interpretation and Bioinformatics Bottlenecks

Despite the advances in transcriptomic technologies, data complexity and bioinformatics limitations remain substantial challenges hindering market growth. Transcriptomic analyses-especially using RNA-seq-generate enormous volumes of data, often reaching hundreds of gigabytes per sample. Extracting meaningful insights from these datasets requires sophisticated algorithms, powerful computational infrastructure, and expertise in bioinformatics. The European Bioinformatics Institute (EMBL-EBI) and NIH's National Center for Biotechnology Information (NCBI) host large-scale transcriptomic repositories such as GEO (Gene Expression Omnibus) and ArrayExpress. However, interpreting this data requires integration with proteomics, genomics, and clinical phenotypes, which adds further layers of complexity. For many healthcare providers and small research labs, this technical requirement becomes a major barrier.

According to a 2022 survey by the Global Alliance for Genomics and Health (GA4GH), more than 60% of genomics labs identified a shortage of bioinformatics talent as a significant operational bottleneck. Furthermore, inconsistencies in data normalization, quality control, and analysis pipelines often lead to irreproducible results, limiting the translational utility of transcriptomics in clinical settings. Another related challenge is the need for standardized bioinformatics workflows. While initiatives such as the FDA's SEQC (Sequencing Quality Control) Project aim to establish quality benchmarks, globally accepted standards for transcriptomic data interpretation are still evolving. Until data analysis becomes more user-friendly and standardized across platforms, the complexity of transcriptomic datasets will continue to restrain broader adoption in clinical and research domains.

Key Market Trends

Integration of Multi-Omics Approaches in Disease Research

A growing trend in transcriptomics is its integration with other omics technologies, including genomics, proteomics, epigenomics, and metabolomics, to provide a holistic view of biological systems. This multi-omics approach enhances the understanding of complex disease mechanisms by correlating gene expression profiles with protein activity, epigenetic modifications, and metabolic changes. The U.S. National Cancer Institute (NCI) has launched several multi-omics initiatives, including the Human Tumor Atlas Network (HTAN), which maps tumors using transcriptomics, genomics, and imaging. The goal is to understand how tumors evolve over time and how patients respond to therapy, enabling the development of personalized treatment plans.

Similarly, the UK Biobank, backed by the UK government and Wellcome Trust, is increasingly adding transcriptomic data to its already vast genomic and clinical dataset. This allows researchers to connect gene expression patterns with real-world disease outcomes in a population-scale setting. This trend is not limited to developed countries. India's GenomeIndia project, supported by the Department of Biotechnology, is also moving towards the integration of transcriptomics with proteomic and metabolomic data to understand ethnic-specific disease vulnerabilities. Such integrative research helps in discovering novel drug targets, stratifying patients for clinical trials, and predicting disease progression. With advancements in artificial intelligence (AI) and machine learning (ML), multi-omics data integration is becoming more feasible, driving deeper biological insights and fueling demand for transcriptomic technologies.

Key Market Players

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

Report Scope:

In this report, the Global Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transcriptomics Market, By Component:

• Instruments
• Consumables
• Software & Services

Transcriptomics Market, By Technology:

• Next Generation Sequencing
• Polymerase Chain Reaction
• Microarray
• In-Situ Hybridization
• Others

Transcriptomics Market, By Application:

• Drug Discovery & Development
• Cell Biology
• Single Cell Analysis
• Gene Expression
• Others

Transcriptomics Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Transcriptomics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Transcriptomics Market.

Available Customizations:

Global Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component (Instruments, Consumables, Software & Services)
  • 6.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization, Others)
  • 6.2.3. By Application (Drug Discovery & Development, Cell Biology, Single Cell Analysis, Gene Expression, Others)
  • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Component
  • 6.3.2. By Technology
  • 6.3.3. By Application
  • 6.3.4. By End User
  • 6.3.5. By Region

7. North America Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User

8. Europe Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Transcriptomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Transcriptomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Asia-Pacific Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. India Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Transcriptomics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Component
      • 9.3.4.2.2. By Technology
      • 9.3.4.2.3. By Application
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Transcriptomics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Component
      • 9.3.5.2.2. By Technology
      • 9.3.5.2.3. By Application
      • 9.3.5.2.4. By End User

10. South America Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Middle East and Africa Transcriptomics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Component
  • 11.2.2. By Technology
  • 11.2.3. By Application
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Transcriptomics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Component
      • 11.3.1.2.2. By Technology
      • 11.3.1.2.3. By Application
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Transcriptomics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Component
      • 11.3.2.2.2. By Technology
      • 11.3.2.2.3. By Application
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Transcriptomics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Component
      • 11.3.3.2.2. By Technology
      • 11.3.3.2.3. By Application
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Transcriptomics Market

16. Competitive Landscape

• 16.1. Agilent Technologies, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. ANGLE plc.
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. Becton, Dickinson, and Company
• 16.5. Fluidigm Corporation
• 16.6. BioSypder, Inc.
• 16.7. Danaher Corporation
• 16.8. 10x Genomics, Inc.
• 16.9. Pacific Biosciences of California, Inc.
• 16.10. NanoString Technologies, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer